Karolinska Development AB
Clanotech granted Orphan Drug Designation by the U.S. FDA
Karolinska Development AB 27.03.2015 08:15 Dissemination of a Adhoc News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- STOCKHOLM - March 27, 2015. Karolinska Development AB (STO: KDEV), a leading Nordic investor in life sciences, today notes that the portfolio company Clanotech AB has received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its candidate drug CLT-288643 for the use as adjuvant treatment to surgery in glaucoma patients. Clanotech's lead compound CLT-28643, an α5β1-integrin antagonist, has anti-angiogenic, anti-fibrotic and anti-inflammatory properties. Based on promising preclinical data in animal models for glaucoma, CLT-28643 has the potential to regulate wound healing processes following glaucoma surgery. 'Clanotech is focused on an important therapeutic area as incorrect healing after surgical intervention of glaucoma often is detrimental to maintaining vision. Karolinska Development is a dedicated investor that is focused on innovative treatments that address unmet medical needs and the received orphan drug designation confirms Clanotech's strategically fit in our portfolio', says Jim Van heusden, CEO of Karolinska Development. For more information on the Orphan Drug Designation and Clanotech please visit: www.clanotech.se For further information, please contact: Jim Van heusden, CEO, Karolinska Development AB Phone: +46 72 858 32 09, e-mail: jim.van.heusden@karolinskadevelopment.com TO THE EDITORS About Karolinska Development AB Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into differentiated products that can be partnered. The business model is to: SELECT the most commercially attractive medical innovations that can potentially satisfy unmet medical needs; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. For more information, please visit www.karolinskadevelopment.com. Karolinska Development is listed on NASDAQ OMX (STO: KDEV). Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act. News Source: NASDAQ OMX 27.03.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Karolinska Development AB Sweden Phone: Fax: E-mail: Internet: ISIN: SE0002190926 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden